This web site is part of the Business Intelligence Division of Informa PLC
This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.
Drug Names(s): ChimeriVax-Dengue, CYD dengue
Description: The ChimeriVax technology utilizes yellow fever virus (YF) 17D vaccine strain capsid and nonstructural genes to deliver the envelope gene of other flaviviruses as live-attenuated chimeric viruses.
Deal Structure: The lead responsibility for clinical testing and development was passed during 2005 to Sanofi pasteur (SP), to whom Acambis licensed worldwide rights.
In July 2008, Sanofi-aventis announced it reached an agreement with Acambis on the terms of a unanimously recommended cash offer for the entire issued and to be issued share capital of Acambis. The acquisition was completed in September 2008.
Pink Sheet FDA Performance Tracker: CBER Approvals
Additional information available to subscribers only: